PL-8177: the oral melanocortin trying to calm inflammation from inside the gut

The system's calming arm, held to one place — a melanocortin told to settle the gut and go no further.

PL-8177 is a good reminder that the melanocortin system does more than pigment and appetite. Its third great role is calming inflammation — the natural signal α-MSH is a potent anti-inflammatory molecule — and PL-8177 is an attempt to turn that biology into a drug for inflammatory bowel disease.^[3] It is one of Palatin Technologies' investigational melanocortin agents, a selective MC1R agonist.^[1]

An oral peptide that doesn't need to be absorbed

The clever part is the delivery. Peptides are usually poor oral drugs because the gut digests them before they can reach the bloodstream — but PL-8177 turns that problem into a non-issue by not trying to reach the bloodstream at all. It is formulated to act locally, delivering the peptide to the lining of the colon, where in early testing it produced sustained colonic exposure with essentially no systemic absorption.^[2] Because its target — MC1R on the colon's epithelial cells — is right there in the gut, staying in the gut is a feature, not a failure. It is the exception that clarifies the rule: oral peptides struggle when they need to travel, not when they act where they land.

The ulcerative colitis signal

PL-8177's lead program is in ulcerative colitis, an inflammatory disease of the colon. A Phase 2 study of once-daily oral PL-8177 in active disease reported positive topline signals for clinical remission and response.^[1] The honest caveat matters, though: Palatin stopped enrollment early — at 12 patients rather than the larger planned cohort — as it redirected resources toward its melanocortin obesity programs and out-licensing discussions.^[2] With those numbers the study was not powered to demonstrate statistical significance, so the result is an encouraging signal rather than proof.

The honest bottom line

PL-8177 is early, and its own developer has shifted focus, so its future is uncertain. But it is a clean illustration of the melanocortin system's anti-inflammatory arm being engineered into a drug — and of a smart way around the oral-peptide problem when the target sits in the gut. For the biology it draws on, see α-MSH; for where it sits among everything in development, see the melanocortin pipeline.

Common questions

What is PL-8177?+

PL-8177 is an investigational oral melanocortin drug from Palatin Technologies — a selective MC1R agonist being developed for inflammatory bowel disease, starting with ulcerative colitis. It works by turning on the melanocortin system’s natural anti-inflammatory signalling in the gut.

How can PL-8177 be oral if it is a peptide?+

By not needing to be absorbed. PL-8177 is a cyclic peptide formulated to act locally on the lining of the colon rather than enter the bloodstream — in early testing it reached the colon with essentially no systemic exposure. It sidesteps the usual oral-peptide problem because its target is the gut wall itself, not a distant organ.

Does PL-8177 work in ulcerative colitis?+

A Phase 2 study in active ulcerative colitis reported positive topline signals for clinical remission and response with once-daily oral dosing. But the trial was cut short — enrolled at 12 patients rather than the planned larger cohort — as Palatin redirected resources toward its obesity programs, so it was not powered to prove statistical significance. The signal is encouraging but preliminary.

References

1. 1.Palatin Technologies. Positive topline results from Phase 2 ulcerative colitis study of oral MC1R agonist PL8177. Press release — clinical remission and response signals. 2025. link ↗
2. 2.Palatin Technologies. Completion of patient enrollment in Phase 2 study of orally administered melanocortin agonist PL8177 in ulcerative colitis. Press release — oral, colon-targeted formulation and trial design. 2024. link ↗
3. 3.Peptides (via PubMed). α-Melanocyte stimulating hormone, inflammation and human melanoma. On the anti-inflammatory activity of melanocortin signalling. 2005. link ↗